Annexon, Inc. (ANNX)

US — Healthcare Sector

Peers: DBVT LRMR ALT KRRO ENGN LBRX AURA KYTX ACIU DMAC

Automate Your Wheel Strategy on ANNX

With Tiblio's Option Bot, you can configure your own wheel strategy including ANNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

ANNX
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

image for news Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

Annexon Biosciences to Participate in Upcoming September Investor Conferences

ANNX
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq.

image for news Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon: Lead GBS Therapy Stokes Near-Term Potential

ANNX
Published: July 14, 2025 by: Seeking Alpha
Sentiment: Negative

Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, given the lack of FDA-approved therapies and limited competition. The company faces near-term risks: delayed regulatory filings, high cash burn, and a likely need for additional funding within a year.

image for news Annexon: Lead GBS Therapy Stokes Near-Term Potential

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ANNX
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission

image for news Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

image for news Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

About Annexon, Inc. (ANNX)

IPO Date 2020-07-24
Website https://www.annexonbio.com
Industry Biotechnology
CEO Douglas E. Love
Employees 106

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.